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Background: Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring
analytical treatment interruption (ATI) in study participants. Little is known about the safety of ATI and its
long-term impact on patient health.
Objectives: ATI safety was assessed and potential biomarkers predicting viral rebound were evaluated.
Methods: PBMCs, plasma and CSF were collected from 11 HIV-1-positive individuals at four different timepoints
during ATI (NCT02641756). Total and integrated HIV-1 DNA, cell-associated (CA) HIV-1 RNA transcripts and
restriction factor (RF) expression were measured by PCR-based assays. Markers of neuroinflammation and neur-
onal injury [neurofilament light chain (NFL) and YKL-40 protein] were measured in CSF. Additionally, neopterin,
tryptophan and kynurenine were measured, both in plasma and CSF, as markers of immune activation.
Results: Total HIV-1 DNA, integrated HIV-1 DNA and CA viral RNA transcripts did not differ pre- and post-ATI.
Similarly, no significant NFL or YKL-40 increases in CSF were observed between baseline and viral rebound.
Furthermore, markers of immune activation did not increase during ATI. Interestingly, the RFs SLFN11 and
APOBEC3G increased after ATI before viral rebound. Similarly, Tat-Rev transcripts were increased preceding viral
rebound after interruption.
Conclusions: ATI did not increase viral reservoir size and it did not reveal signs of increased neuronal injury or in-
flammation, suggesting that these well-monitored ATIs are safe. Elevation of Tat-Rev transcription and induced
expression of the RFs SLFN11 and APOBEC3G after ATI, prior to viral rebound, indicates that these factors could be
used as potential biomarkers predicting viral rebound.
Introduction
Combination ART (cART) is able to suppress viral replication in
HIV-1-infected individuals, but cannot eradicate HIV-1. Lifelong
cART remains mandatory as the latent viral reservoir fuels viral
replication after treatment interruption, rendering HIV-1 a chronic
disease. This latent HIV-1 reservoir is the last hurdle towards an
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HIV-1 cure and consequently the target of cure strategies. Most of
these cure strategies comprise a multitarget approach, both acti-
vating the latent reservoir and enhancing the immune response,
e.g. shock and kill.1 The lack of biomarkers assessing reservoir re-
duction or virological control means that analytical treatment
interruption (ATI) trials are becoming the gold standard to evalu-
ate the potency of cure strategy interventions.2,3 Although these
intensively monitored ATIs are well tolerated by most of the partic-
ipants, little is known about ATI safety and its long-term impact on
patient health.4,5 Recent reports demonstrated no changes in
viral reservoir size [total HIV-1 DNA, intact HIV-1 DNA (near full-
length) and cell-associated (CA) HIV-1 RNA] and little diversity in
composition of virus populations pre- and post-ATI.6–8 These data
are reassuring, but additional analyses evaluating virological and
immunological characteristics in different body compartments
pre- and post-ATI are crucial for further safety assessment.
Neopterin, kynurenine and kynurenine/tryptophan ratio are
commonly assessed immune activation markers in plasma and
CSF and, further, YKL-40 and neurofilament light chain (NFL)
are used as markers of neuroinflammation and neuronal injury,
respectively.9,10 Increased levels of these markers have been
detected in several diseases characterized by persistent inflamma-
tion (e.g. Alzheimer’s disease, cancer and viral infections, including
HIV-1).10–12 Hence, assessing neopterin, kynurenine, kynurenine/
tryptophan ratio, YKL-40 and NFL in CSF pre- and post-ATI could
inform on the potential consequences of ATI on the brain.
Longer periods of treatment interruptions have been associ-
ated with increased CNS inflammation and NFL, as signs of
neuronal injury.13
ATI, combined with extensive patient sampling, could give
broader insights into the origin of viral rebound and can help iden-
tify potential biomarkers for predicting the time to viral rebound
(TTVR) after treatment interruption.14
Because restriction factors (RFs), antiviral factors acting at
specific stages of the viral life cycle, are induced early upon HIV-1
infection, after IFN production,15 these factors could be potential
biomarkers for TTVR. Mechanisms that drive RF expression are not
fully elucidated and measurement of RF levels in vivo before, dur-
ing and after ATI could contribute to understanding the timing
of RF induction. The best-characterized RFs include bone marrow
stromal cell antigen 2 (BST2)/tetherin, apolipoprotein B mRNA-
editing enzyme catalytic subunit 3G (APOBEC3G), SAM domain-
and HD domain-containing protein 1 (SAMHD1) and tripartite
motif-containing protein 5 (TRIM5), each performing its antiviral
activity at different stages of the viral replication cycle (inhibition of
virion release, viral hypermutation at reverse transcription, deple-
tion of dNTP pool and targeting the viral capsid, respectively).16
Other RFs have been described recently, such as MX2, SLFN11 and
PAF1, interfering with nuclear import, translation of viral RNA and
other early events in the replication cycle.16–18 The HIV-1 genome
encodes accessory proteins able to counteract RF activity, such as
viral infectivity factor (Vif), viral protein U (Vpu), negative regulatory
factor (Nef) and viral protein R (Vpr),19 allowing virus replication to
continue.20 In vivo RF data are limited, but their expression was
found to be positively correlated with IFN-stimulated gene (ISG)
levels and to viral load (VL) for some factors (APOBEC3G, TRIM5
and MX2).21,22 Additionally, APOBEC3G, TRIM5, BST2 and MX2
expression levels are increased in seroconverters (SRCVs),23 ART-
naive acutely infected HIV-1 patients, confirming RF expression is
induced as an early antiviral defence mechanism of the host im-
mune system and suggesting that RF levels could be induced early
post-ATI. In addition, the determination of different CA HIV-1 RNA
transcripts during ATI can potentially give insights into RF activity.
TAR, long LTR, polyA, Pol and Tat-Rev transcripts represent tran-
scription initiation, elongation, termination, CA unspliced HIV-1
RNA (usRNA) and multiply spliced HIV-1 RNA (msRNA), respective-
ly. Levels of HIV-1 msRNA indicate the ability to overcome blocks
to transcription initiation, elongation and termination and were
reported to increase at viral rebound.24,25
To assess ATI safety and to identify markers that could predict
viral rebound, we explored markers of inflammation, viral reservoir
size and RF expression levels at four different timepoints before,
during and after ATI [baseline on cART (T1; undetectable VL), post-
ATI (T2; undetectable VL), at viral rebound (T3; detectable VL) and
3 months after restart of cART (T4; undetectable VL)].
Methods
Patient cohort
The HIV-STAR ATI trial was designed to identify and characterize the rele-
vant anatomical compartment(s) of the replication-competent HIV reser-
voir (trial registry number on clinicaltrials.gov: NCT02641756). The study
was conducted between 1/1/2016 and 1/12/2017. The primary outcome of
this study was published recently.14 The study protocol, experimental de-
sign and recruitment strategy were approved by the Ethics Committee of
the University Hospital of Ghent (Belgian registration numbers:
B670201525474 and B670201628230). All participants provided written
consent. Participants were recruited from the AIDS reference centre at the
Ghent University Hospital depending on strict inclusion criteria and after in-
tensive counselling. Eleven HIV-1-infected, long-term-treated participants
under chronic cART were included. In a second phase of the study, treat-
ment was interrupted and participants were monitored twice a week with
VL measurements and, upon viral rebound, treatment was reinitiated im-
mediately at T3, which was defined by a VL >1000 copies/mL or two con-
secutive measurements >200 copies/mL. The study design allowed us to
further investigate virological and immunological characteristics and their
relationship with viral rebound. All participants are included in the current
substudy.
RF and viral reservoir markers (total HIV-1 DNA, integrated HIV-1 DNA
and different transcripts of CA HIV-1 RNA indicating specific transcriptional
blocks: TAR, long LTR, Pol, polyA and Tat-Rev) were measured in PBMCs at
T1 (on cART, undetectable VL), T2 (7–15 days after ATI, undetectable VL),
T3 (viral rebound, detectable VL) and T4 (3 months after cART restart)
(Figure 1). Additionally, inflammation markers were determined in
plasma at these four different timepoints and for 10/11 participants at T1
and T3 in CSF.
Quantitative real-time PCR
RNA was extracted from 107 PBMCs (RNA innuPREP Mini Kit, Analytik,
Germany) and reverse-transcribed into cDNA using the qScript cDNA
SuperMix (Quantabio, MA, USA) according to the manufacturer’s protocol.
Real-time PCR was performed as previously described.23 Table S1 (available
as Supplementary data at JAC Online) depicts used assays. Reference gene
stability was assessed for ACTB, GAPDH, TBP, B2M, YWHAZ, PLOD1, HMBS and
UBC on a subset of the samples. ACTB, GAPDH and YWHAZ were selected for
normalization after analysis with the GeNorm algorithm.26 Expression ana-
lysis was performed with qbase! software (Biogazelle).27
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Neuroinflammation markers
NFL and YKL-40 protein were measured in CSF as markers of neuronal injury
and neuroinflammation, respectively. In addition, neopterin, tryptophan
and kynurenine were measured, both in plasma and CSF, as markers of
immune activation. NFL concentration was measured using an in-house
ELISA, as previously described in detail.28 YKL-40 concentration was meas-
ured using a commercially available ELISA according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA). NFL and YKL-40 meas-
urements were performed by board-certified laboratory technicians in one
round of experiments with baseline and follow-up samples side by side on
the ELISA plates to minimize variation. Intra-assay coefficients of variation
were below 8% for both NFL and YKL-40. Neopterin was measured by ELISA
(BRAHMS, Hennigsdorf, Germany) and kynurenine, for calculation of
the kynurenine/tryptophan ratio, by HPLC.29
For details on the amplification of V1–V3 env from CSF and the phyl-
ogeny estimation, we refer to our recently published paper.14
Total and integrated HIV-1 DNA
Total genomic DNA was extracted from 107 PBMCs (DNeasy Blood & Tissue
Kit, QIAGEN, The Netherlands). Restriction and digital droplet PCR (ddPCR)
reactions were performed as described previously.30 Reference gene ribo-
nuclease P/MRP subunit p30 (RPP30) was used for normalization and quan-
tification of total HIV-1 DNA was performed with ddpcRquant, an in-house-
developed software.31 Integrated HIV-1 DNA was quantified using the re-
petitive sampling Alu-HIV PCR method involving a nested-PCR approach.32
This method was performed as described previously.23 Briefly, in the first
PCR, a forward primer and a reverse primer, targeting a human Alu frag-
ment and the HIV-1 gag region, respectively, were used to quantify 40 repli-
cates. Additionally, 20 replicates of background quantification were
performed using only the HIV-1 gag primer.23
CA HIV-1 RNA transcripts
RNA was extracted from 107 million PBMCs (RNA innuPREP Mini Kit). TAR,
long LTR, polyA, Pol and Tat-Rev CA HIV-1 RNA transcripts were quantified
as described previously by Yukl et al.24 Input for reverse transcription (RT)
reactions was maximized based on RNA mass recovery: a median of 0.385
and 3.286lg for (i) TAR and (ii) long LTR, Pol, polyA and Tat-Rev RT, respect-
ively, was used. Normalization was performed depending on input RNA
mass as previously described.24
Statistical analysis
Non-parametric Friedman test with post hoc Dunn statistical analysis was
performed. Holm P value adjustment method was used for multiple
comparisons. Spearman correlation analysis was performed to define sig-
nificant correlations between RFs, neuroinflammation markers and im-
munological and virological reservoir parameters at single timepoints.
Additionally, repeated measurements correlation analysis was performed
to detect similar or antagonistic profiles for these markers at the different
timepoints. Statistical analyses and graphing was performed with R soft-
ware using the following packages: PMCMR, Hmisc, graphics, ggplot2, corr-
plot and rmcorr.33
Results
Study participants
Eleven HIV-1-infected individuals were included in this study and
sampled at four timepoints pre- and post-ATI (Figure 1).
Participants were on stable cART for3 years and did not have sig-
nificant comorbidities at the time of inclusion. CD4 nadir values
were >300 cells/mm3 for all but one participant (Table 1).
Participants received a standard cART regimen involving an inte-
grase inhibitor for at least 3 months before study inclusion. The
median age of the participants was 40 years (range 32–56)
(Table 1). Median TTVR was 21 days (range 15–36) with a median
HIV-1 RNA level of 3.29 log copies/mL (range: 3.23–3.64) at viral re-
bound. Demographic variables are available in Table 1.
Quantification of viral reservoir change during ATI: size
and activity
Levels of total and integrated HIV-1 DNA were determined at the
four timepoints during ATI to further assess the stability of the viral
reservoir and ATI safety. No remarkable changes at the different
timepoints were detected for either marker (Figure 2a and b).
Spearman correlation analysis at T1, T2, T3 and T4 revealed a
highly significant positive correlation between total and integrated
HIV-1 DNA levels (Spearman R = 0.75, R = 0.90, R = 0.90 and
R = 0.90, respectively).
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Figure 1. Schematic overview of the study set-up. PBMCs were collected
at four different timepoints (T1, T2, T3 and T4). CSF was collected at two
timepoints (T1 and T3). T1 represents the sampling under cART (baseline;
undetectable VL). ATI occurs at Day 0. T2 represents 7–15 days after ATI
(undetectable VL). At T3, viral rebound occurs (detectable VL). T4 repre-
sents a timepoint after cART restart (approximately 3 months; undetect-
able VL).
Table 1. Clinical and virological characteristics of HIV-STAR ATI trial
patients; n = 11. Values shown are median (IQR)
Clinical characteristics
age (years) 40 (37.5–46.5)
time on cART (years) 4 (3–7)
CD4 nadir (cells/mm3) 378 (329–413)
CD4 count at T1 (cells/mm3) 688 (616.5–872)
CD4/CD8 at T1 1.05 (0.935–1.33)
Virological characteristics
VL zenith (log copies/mL) 4.8 (4.48–5.05)
VL at rebound (log copies/mL) 3.29 (3.23–3.64)
TTVR (>1000 copies/mL) (days) 21 (20.5–26.5)
Assessing the immunovirological effect of viral rebound JAC
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TAR, long LTR, polyA, Pol and Tat-Rev HIV-1 RNA transcripts
were determined at the different timepoints and exhibited peak
levels at T3. Significant increases were detected for long LTR,
polyA, Pol and Tat-Rev at T3 compared with T1 and T4 (T1:
P < 0.0001, P < 0.0001, P = 0.0006 and P = 0.0002, respectively; T4:
P < 0.0001, P = 0.019, P = 0.001 and P = 0.0077, respectively;
Figure 2c). Repeated measurement correlations indeed indicated
highly significant positive correlation between TAR, long LTR,
polyA, Pol and Tat-Rev RNA transcription levels at the four time-
points. Interestingly, Tat-Rev levels were also significantly elevated
at T2 compared with T1 (P = 0.016) (Figure 2c).
No increased inflammation in plasma and CSF after ATI
No significant increase in NFL or YKL-40 in CSF was observed be-
tween baseline (T1) and viral rebound (T3) (Figure 3a).
Furthermore, markers of immune activation (neopterin, kynure-
nine and kynurenine/tryptophan ratio) were also found to be sta-
ble in CSF (Figure 3b). Similarly, plasma levels of
neuroinflammatory markers did not increase during viral rebound
(Figure 3c). Interestingly, neopterin levels in CSF pre-ATI were
negatively correlated with time on treatment (P = 0.004), suggest-
ing that CNS inflammation decreases with time on cART.
To further investigate viral replication in the CNS, the CSF-
derived virus at T1 and T3 was sequenced for five patients. There
was no clear sign for compartmentalization in the CNS (Figure 3d).
Rebound lineages in CSF were more closely related to rebound line-
ages found in plasma compared with those found in CSF on cART,
rendering it unlikely that these emerged from pre-existing CSF line-
ages. Rather, these most probably represent rebounding virus that
crossed the blood–brain barrier, which is also indicated by the fact
that at least one of the T3 CSF sequences was identical to a re-
bound virus in 2/5 patients (Figure 3d).
SLFN11 and APOBEC3G expression elevation prior to
viral rebound
IFIT1 and MX1 are well-characterized ISGs and were used as
markers for IFN exposure. They do not specifically interfere with
HIV. Significant MX1 up-regulation was detected at viral rebound
(T3) compared with timepoints with undetectable VL (T1, T2 and
T4; P = 0.03, P = 0.02 and P = 0.01, respectively; Figure 4a). Similarly,
IFIT1 levels demonstrated up-regulation at viral rebound (T3)
compared with T1 (P = 0.001), suggesting that IFN induction is
linked to active replication (Figure 4a). As most RFs are also induced
by IFN, we wanted to determine whether APOBEC3G, SAMHD1,
BST2, TRIM5, MX2, SLFN11 and PAF1 expression profiles would
follow IFIT1 and MX1 levels and therefore exhibit peak expression
at viral rebound (T3). Additionally to RFs, we hypothesized that
expression levels of two HIV-1 dependency factors (NLRX1 and
PSIP1) could also be linked to VL levels.
Levels of the RFs MX2, TRIM5 and BST2 followed this assumption
and on average reached their highest level at T3 although not
reaching statistical significance for TRIM5 and BST2 (Figure 4b).
SAMHD1 and PAF1 expression did not significantly change during
ATI (Figure 4c). Similarly, HIV-1 dependency factors, NLRX1 and
PSIP1, involved in inhibition of IFN response and encoding the inte-
grase cofactor LEDGF/75, demonstrated no significant differences
in expression levels between the different timepoints during ATI
(Figure 4d). Surprisingly, SLFN11 demonstrated significant up-
regulation at T2, which is post-ATI, but with still undetectable VL,
compared with T1 and T4 (P = 0.002 and P = 0.049, respectively).
APOBEC3G followed a similar pattern to SLFN11, although up-
regulation at T2 was not significant (Figure 4e). Repeated
measurements correlation analysis demonstrated a highly signifi-
cant correlation between SLFN11 and APOBEC3G over the four
timepoints (R = 0.80 and P < 0.0001), indicating their similar
expression profiles (Figure S1).
RF expression levels are not correlated with TTVR
Because SLFN11 and APOBEC3G levels are up-regulated before
plasma VL becomes detectable, we tested whether their expres-
sion was linked to TTVR and therefore could be used as a predictive
marker. However, no association between expression levels of
SLFN11, APOBEC3G or other antiviral factors and TTVR was
detected. Interestingly, levels of total and integrated HIV-1 DNA at
T1 and T2 were positively correlated with VL levels at rebound (T3)
(T1: R = 0.52 and R = 0.70, respectively; T2: R = 0.9 and R = 0.85,
respectively; Figure S2), suggesting that a larger viral reservoir gives
rise to higher plasma VL levels.
Discussion
ATIs remain the gold standard to evaluate new possible HIV-1
cure strategies as we lack surrogate biomarkers that are able to as-
sess the efficiency of cure strategies and their impact on TTVR after
treatment interruption. In addition, the safety of these ATIs and
the long-term effect on the HIV reservoir in the blood or other com-
partments is unclear. The primary research objective of the HIV-
STAR ATI trial was to identify the origin of viral rebound after ATI by
comparing proviral V1–V3 env sequences from different reservoirs
[blood, lymph node, gut-associated lymphoid tissue (GALT), brain]
with viral sequences found in plasma after ATI.14 We could not
find any sign of compartmentalization by analysing more than
4000 sequences in these 11 participants and concluded that re-
bound is a heterogeneous process, involving different anatomical
reservoirs and cellular subsets. In the present substudy, the effect
of ATI on the viral reservoir size and inflammation status was eval-
uated at different timepoints before, during and after ATI to fur-
ther address these safety concerns. Additionally, our study
investigated the expression levels of HIV-1 RFs, dependency fac-
tors and the expression of different CA viral RNA transcripts defin-
ing distinct blocks to transcription at these timepoints to identify
possible biomarkers for viral rebound.
Safety concerns in ATI trials: reservoir size, activity and
inflammation
ATI did not increase levels of total and integrated HIV-1 DNA over
the four different timepoints or of the different CA HIV-1 RNA tran-
scripts pre- and post-ATI (T1 versus T4). These data are consistent
with previous findings and indicate a stable viral reservoir after a
short period of treatment interruption.6,7 Interestingly, levels of
total and integrated HIV-1 DNA at T1 and T2 were positively corre-
lated with VL levels at rebound (T3), suggesting that HIV-1-
positive individuals with a larger viral reservoir before ATI have
higher plasma VL levels at viral rebound.
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Figure 2. Viral reservoir size quantification at the four different timepoints during ATI. Levels of total HIV-1 DNA (a) and integrated HIV-1 DNA (b) at
T1, T2, T3 and T4. Levels for the different transcripts (TAR, long LTR, polyA, Pol and Tat-Rev) of CA HIV-1 RNA (c) at T1, T2, T3 and T4. Friedman statis-
tical analysis with post hoc Dunn test was performed. Significant P values are indicated in red. This figure appears in colour in the online version of JAC
and in black and white in the print version of JAC.
Assessing the immunovirological effect of viral rebound JAC
1315
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/75/5/1311/5735421 by guest on 22 M
ay 2020
STAR
STAR002
STAR003
STAR004
STAR005
STAR006
STAR007
STAR008
STAR009
STAR010
STAR011
STAR012
600
500
400
300
P = 0.998
nm
ol
/L
NFL(a)
(b)
(c)
(d)
T1 T3
150000
125000
100000
75000
P = 0.554
nm
ol
/L
YKL–40
T1 T3
9
8
7
6
5
P = 0.124
nm
ol
/L
Neopterin
T1 T3
0.100
0.075
0.050
P = 0.865
nm
ol
/L
Kynurenine
T1 T3
40
35
30
25
20
15
P = 0.375
nm
ol
/L
Kyn/Trp
T1 T3
30
20
10
P = 0.010
nm
ol
/L
Neopterin
T1 T3 T4T2
STAR3
STAR8
STAR4
STAR11
STAR7
Provirus on cART (T1)
Plasma at rebound (T3)
CSF on cART (T1)
CSF at rebound (T3)
2.5
2.0
1.5
1.0
P = 0.329
nm
ol
/L
Kynurenine
T1 T3 T4T2
45
40
35
30
25
20
P = 0.167
nm
ol
/L
Kyn/Trp
T1 T3 T4T2
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Figure 4. ISG, RF and HIV-1 dependency factor expression levels at four timepoints during ATI. Normalized relative quantity levels at T1, T2, T3 and
T4 for: (a) MX1 and IFIT1; (b) MX2, TRIM5 and BST2; (c) SAMHD1 and PAF1; and (d) NLRX1 and PSIP1. Friedman statistical analysis with post hoc Dunn
test was performed. Significant P values are indicated in red. NRQ, normalized relative quantity. This figure appears in colour in the online version of
JAC and in black and white in the print version of JAC.
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We further assessed the effect of ATI on the HIV brain
compartment. No detectable signs of neuronal injury or major CNS
inflammation during viral rebound in plasma after (short) ATI
were found, indicating that it is very unlikely that extensive replica-
tion in CNS was ongoing this early after treatment cessation. This is
in line with the limited sequencing data that we obtained from
CSF, which showed no signs of strong compartmentalization or of
early rebound by CSF lineages.
These data supplement previous published results depicting
that ATI combined with close monitoring is safe for the patient.6–8
However, two cases of HIV sexual transmission during treatment
discontinuation within an ATI were reported recently,34,35 suggest-
ing that considering the use of pre-exposure prophylaxis in
seronegative partners should be advised in future ATI studies.
RF analysis
Expression of RFs and ISGs at the different timepoints was eval-
uated to find possible biomarkers predicting viral rebound. Levels
of ISGs and the RFs MX2, TRIM5 and BST2 had a similar profile over
time, peaking at the time VL became detectable (T3), suggesting
that VL drives ISG and RF expression. These findings are in line with
previous reports linking the levels of several RFs and VL in different
cohorts of HIV-1-positive individuals.21,23 Interestingly, we found
that SLFN11 and APOBEC3G were induced prior to other RFs and
prior to the time of viral rebound (T3) and therefore could have the
potential to serve as biomarkers predicting viral rebound after ATI.
Elevated SLFN11 expression has been linked to long-term non-pro-
gressor (LTNP) status and reduced viral reservoir size,21,23 suggest-
ing a role for SLFN11 in VL control. Therefore, early induction of
SLFN11 could be a host defence mechanism attempting to control
the virus. Yet, we could not find a correlation between the up-
regulation of SLFN11 and APOBEC3G and TTVR. We also did not
identify significant links between TTVR and expression of other RFs,
participant characteristics (time since primary infection, time on
cART, time before cART initiation), virological (total HIV-1 DNA,
integrated HIV-1 DNA, VL zenith) and immunological (CD4 nadir)
parameters (data not shown). Surprisingly, at T1 (cART; undetect-
able VL), a strong negative correlation was detected between ex-
pression levels of antiviral factors (MX1, IFIT1, APOBEC3G, PAF1,
SAMHD1 and SLFN11) and NK cell count. Lower NK count and
higher RF expression levels in ART-treated individuals have been
linked to lower immune activation and better preservation of im-
mune responses, respectively.
Reservoir activity prior to detectable VL
Another finding that merits further investigation is the expression
profile of CA HIV-1 RNA transcripts defining distinct blocks to tran-
scription during ATI. Transcription of TAR, long LTR, polyA, Pol and
Tat-Rev fragments tended to be up-regulated at viral rebound
(T3). Interestingly, increased Tat-Rev expression preceded viral re-
bound, whereas for other transcripts the increase coincided with
the timepoint of viral rebound (T3). Tat-Rev transcription indicates
the ability to overcome blocks to transcription initiation, elongation
and termination and therefore might be a suitable marker for
forthcoming viral rebound.24,25 To note, although Tat-Rev tran-
script levels were at the lower end of detection, we were able to
pick up quantifiable results by ddPCR, underlining the strength of
this platform for nucleic acid quantification.
Limitations
The current study has several limitations. This ATI trial included
only 11 participants, making it difficult to draw population-based
conclusions. However, the design of ATIs, especially with this ex-
tensive tissue sampling, makes it challenging to include partici-
pants, both from a motivational and a financial point of view.
Second, RF and HIV-1 RNA expression analyses were performed in
PBMCs and not in CD4 T cells or T cell subsets, in contrast to other
studies.8,36 Nonetheless, significant signals could be picked up. If
CD4 T cells could be purified from the PBMC fraction, it can be
expected that the observed signal of HIV-1 transcripts from PBMCs
would increase.
Conclusions
Overall, our data support that ATI is safe and, if combined with
close monitoring and immediate treatment reinitiation at the time
of viral rebound, this intervention can be considered as the final
and most comprehensive read-out of HIV cure trials. ATI did not in-
crease viral reservoir size and it did not reveal signs of increased
neuronal injury or inflammation. Furthermore, ATIs give rise to
unique opportunities to further investigate the viral reservoir in
blood and other anatomical compartments and should be used to
investigate potential biomarkers for viral rebound. Elevation of Tat-
Rev transcription and induced expression of the RFs SLFN11 and
APOBEC3G rapidly after ATI prior to viral rebound indicates that
these factors could be used as potential biomarkers predicting viral
rebound. In this context, evaluating additional timepoints could be
beneficial to see whether these transcripts can be detected even
earlier than T2.
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